Objective: Central nervous system (CNS) serotonin (5-HT) exerts both excitatory and inhibitory effects on the sympathetic nervous system (SNS) in animals. In this study, we examine the effects of tryptophan enhancement and depletion on plasma catecholamine levels in humans. Methods: The total sample consisted of 164 healthy men and women who were tested for 2 days. Seventy-nine participants were randomized to a tryptophan enhancement condition and 85 to a tryptophan depletion condition. Both protocols consisted of a "sham day," followed by an "active day." Blood samples for assessment of plasma norepinephrine and epinephrine levels were collected before and after tryptophan enhancement/depletion. Data were analyzed using general linear models. Separate analyses were conducted for each study arm and for each measure. Results: In the depletion condition, both epinephrine (F(5,330) = 2.69, p = .021) and norepinephrine (F(5,335) = 2.79, p = .018) showed small increases on active versus "sham" depletion days. There were also significant day by time interactions for epinephrine (F(3,171) = 39.32, p < .0001) and norepinephrine (F(3,195) = 31.09, p < .0001) levels in the enhancement arm. Tryptophan infusion resulted in a marked increase in epinephrine (Pre mean = 23.92 (12.23) versus Post mean = 81.57 (62.36)) and decrease in norepinephrine (Pre mean = 257.2 (106.11) versus Post mean = 177.04 (87.15)), whereas levels of both catecholamines were stable on the "sham day." Conclusions: CNS 5-HT exerts both inhibitory and excitatory effects on SNS activity in humans, potentially due to stimulation of CNS 5-HT receptors that have shown to have inhibitory (5-HT 1A ) and excitatory (5-HT 1A and/or 5-HT 2 ) SNS effects in animal models.
INTRODUCTION C
entral nervous system (CNS) serotonergic neurotransmission plays a key role in regulating hypothalamic pituitary adrenocortical (HPA) and several aspects of endocrine (1) and cardiovascular (2, 3) function in humans. It is well established that increasing CNS serotonergic activity with various pharmacological agents stimulates the release of cortisol and other endocrine hormones such as prolactin and growth hormone (4) . Much less is known, however, about the role of CNS 5-hydroxytryptamine (5-HT) in modulating sympathetic nervous system (SNS) activity in humans. Research using animal models suggests that CNS 5-HT exerts both inhibitory and excitatory effects on SNS activity (5, 6) .
The 5-HT 1A receptor is thought to contribute to the inhibitory effect of 5-HT on the SNS (5-7). Raising CNS levels of 5-HT in the cat has been shown to reduce sympathetic neural traffic to the heart via stimulation of 5-HT 1A neurons in the medullary raphe (8, 9) . Stimulation of 5-HT 1A receptors in the medullary raphe by the 5-HT 1A agonist 8-Hydroxy-n,n-dipropylaminotetralin has also been shown to attenuate stress-induced tachycardia in the rabbit (10) .
Thus, it seems that stimulation of 5-HT 1A receptors in the medullary raphe results in a reduction in cardiac sympathetic nerve activity.
CNS 5-HT also has an excitatory effect on SNS activity. 5-HT 3 receptors located in the nucleus tractus solitarius contribute to stress-induced suppression of the baroreflex and at the periphery 5-HT 3 receptors facilitate long-term potentiation in the sympathetic ganglia (11) . A series of studies have shown that stimulation of CNS 5-HT 2 receptors results in tachycardia and vasoconstriction due to increased sympathetic discharge (5) . Stimulation of 5-HT 2 receptors also seems to influence circulating catecholamine levels. Circulating epinephrine is secreted from the adrenal medulla. Norepinephrine is also released by the adrenal medulla, but its primary source is spillover from sympathetic nerves innervating blood vessels (12) . Studies have shown that peripheral administration of a 5-HT 1C/2 receptor agonist to Sprague-Dawley rats resulted in an increase in circulating epinephrine (13, 14) and a slight decrease in circulating norepinephrine (13) . 5-HT 1A receptors have also been shown to contribute to excitatory effects of 5-HT on the SNS. For example, peripheral administration of the 5-HT 1A agonist 8-Hydroxy-n,n-dipropylaminotetralin to Sprague-Dawley rats increases both circulating epinephrine and norepinephrine (13, 14) .
In humans, administration of serotonin reuptake blockers has been shown to cause increased catecholamine levels. One study (15) found that administration of fluoxetine to 12 depressed patients resulted in an increase in epinephrine and norepinephrine compared with healthy patients receiving placebo who showed no changes in those catecholamines. This was the case for both acute and chronic administration of fluoxetine. A study of patients with type 1 diabetes (16) found that 6 weeks of fluoxetine treatment increased the epinephrine and norepinephrine (both counter regulatory hormones) responses to hypoglycemia. The same group found similar effects of chronic (6 weeks) fluoxetine treatment on epinephrine and norepinephrine in response to hypoglycemia in healthy volunteers (17) . To our knowledge, no studies have investigated the effect of enhancing CNS 5-HT on peripheral catecholamine levels in healthy individuals in the normal glycemic state.
In summary, animal and human studies suggest that CNS serotonin has an effect on SNS activity and animal studies suggest that this effect can be both inhibitory and excitatory depending upon the specific receptor involved and the site of action. However, caution should be exercised when extrapolating the findings from other animal species to humans because the specific role of CNS 5-HT in regulating SNS activity may vary across species. Therefore, it is important to determine whether there are similar SNS effects of varying CNS 5-HT activity in humans. The current research study examined the effect of both enhancing and lowering CNS levels of 5-HT, via tryptophan infusion and depletion, respectively, on SNS activity as indexed by plasma levels of norepinephrine and epinephrine. Prolactin and cortisol were also measured to verify that the tryptophan protocol produced adequate CNS serotonergic stimulation using indices of neuroendocrine function that are known to be responsive to tryptophan enhancement (4). Acute tryptophan depletion and enhancement have been shown to be valid techniques for raising and lowering CNS serotonin levels. Depletion of tryptophan, a precursor to 5-HT, has been shown to decrease cerebrospinal fluid levels of serotonin's major metabolite 5-hydroxyindoleacetic acid (18) (19) (20) (21) (22) (23) (24) . This experimental procedure has been widely used in the study of 5-HT in mood and behavior (25) (26) (27) (28) . In addition, intravenous infusion of the 5-HT precursor L-tryptophan acutely increases both CNS 5-HT synthesis and levels of extracellular 5-HT (18, 19, 29) .
METHODS

Participants
Participants were recruited between 1997 and 2002 for a study investigating genetic, behavioral, and environmental mechanisms of cardiovascular disease (30, 31) . The study protocol required that participants be in good current health; therefore, they underwent a comprehensive psychological examination, as well as medical history, physical examination, electrocardiogram, chest radiograph, hemoglobin, hematocrit, white cell count, and blood chemistries to rule out current medical and psychiatric disorders. The use of any prescription or illegal drugs (as detected by a urine screen before entry into study) was grounds for exclusion.
The full-study sample consisted of 164 participants, with 79 randomized to a tryptophan enhancement condition and 85 randomized to a tryptophan depletion condition. Participants were excluded from the analyses if they were missing data on a specific neuroendocrine variable of interest. For the enhancement condition, there were 58 participants with complete data for analyses involving epinephrine and 66 for analyses involving norepinephrine, prolactin, and cortisol. This sample (n = 66) consisted of 24 (36.36%) women, 34 (51.52%) African Americans, and the M (SD) age was 34.83 (8.98) years. For the depletion condition, the sample size was 67 participants for analyses involving epinephrine and 68 participants for analyses involving norepinephrine, prolactin, and cortisol. This sample (n = 68) consisted of 26 women (38.24%), 37 African Americans (54.41%), and the M (SD) age was 33.91 (7.99) years. Analyses comparing the enhancement and depletion groups showed no significant differences between the arms regarding important variables such as age, race, sex, and resting neuroendocrine measures on day 1 (p's range between .14 and .82).
The study was conducted at Duke University Medical Center (DUMC), and all participants gave informed consent before their participation in the study using a form approved by the DUMC Institutional Review Board. Those enrolled in the study received US $500 for their participation.
Procedure
The study was conducted for a 2 1/2-day period at the Duke Clinical Research Center. On the first day, participants were admitted to the Duke Clinical Research Center and underwent a medical examination. The second day of the study served as the placebo condition for the depletion and enhancement arms. Active tryptophan depletion and enhancement occurred on the third day of the study.
Tryptophan Enhancement Protocol
On the day of the active tryptophan infusion, participants were not allowed to eat or drink nor they were allowed to smoke, beginning at 6:30 AM until the completion of all study procedures at approximately 1:30 PM. At 7:00 AM, an intravenous (D5 W/.5 N saline) line was started and kept running at 50 ml/h until 1:30 PM. All participants were seated in a reclined position and activity was limited to watching videos provided by the investigator or playing cards. Bathroom visits were allowed up to the time of tryptophan infusion. At 11:00 AM, participants received a full dose of tryptophan (100 mg/kg body weight) for a period lasting 25 minutes. A blood pressure cuff was placed around the infusion bag and inflated up to a maximum of 35 mm Hg if needed to complete the total dose within 25 minutes. At the end of the infusion, the IV line was returned to D5 W/.5 N saline and the participants continued to sit in a reclined position until 12:00 PM. At 12:00, participants were given a 15-to 20-minute break in which they were allowed to use the bathroom and then they returned to a seated position after which they participated in a 40-minute mental stress protocol (results to be reported elsewhere). Blood samples were obtained at 30 minutes, 45 minutes, and 1 hour after the beginning of infusion. The procedures for the sham tryptophan infusion were identical except that participants received a saline solution.
Tryptophan Depletion Protocol
Those who participated in the tryptophan depletion condition were placed on a 160 mg/d of tryptophan diet for 24 hours before testing. This diet provided adequate protein and energy with minimum tryptophan content. At the end of the 24-hour period, the participants were prepared for the acute tryptophan depletion protocol. During the depletion arm of the study, participants were seated in the same reclined position that was used in the enhancement protocol and not allowed food or liquids, nor they were allowed to smoke, beginning at 6:30 AM until the completion of all study procedures at approximately 1:30 PM. At 7:00 AM, an IV (D5 W/.5 N saline) line was started and kept running at 50 ml/h until 1:30. At 7:30 AM, the participants received a tryptophan-free "milkshake." The milkshake was
Because of the unpleasant taste of L-methionine, L-cysteine, and L-arginine, these amino acids were encapsulated separately and given 15 minutes before they ingested the amino acid milkshake. Participants were given 30 minutes to consume the amino acid milkshake. Blood samples were obtained just before the beginning of the tryptophan depletion process (i.e., 7:30), 30 minutes after ingestion of the amino acid drink (i.e., 8:30) , and at 60-minute intervals during the 4 hours after ingestion of the amino acid drink (i.e., 9:00, 10:00, 11:00, and 12:00). As with the infusion condition, participants were given a 15-to 20-minute break beginning at 12:00 during which they were allowed to use the bathroom. They then returned to a seated position after which they participated in a 40-minute mental stress protocol (results to be reported elsewhere). During the sham tryptophan depletion, the participants consumed an amino acid milkshake identical to the one they drank during the active depletion day, except that this drink also contained tryptophan. All other procedures were identical across the 2 days of testing.
Neuroendocrine Measures
Blood samples for assessment of plasma prolactin, cortisol, norepinephrine, and epinephrine levels were drawn just before the infusion and at 30-minute, 45-minute, and 1-hour postinfusion during both active and sham day for participants completing the tryptophan enhancement protocol. For the depletion condition, blood samples were collected just before participants ingesting the milkshake and at 30 minutes, 1 hour, 2 hours, 3 hours, and 4 hours afterward. Blood samples were spun for 15 minutes in a refrigerated centrifuge, and plasma was transferred into polypropylene tubes containing .05-ml glutathione and then frozen at −70°C. Blood samples were processed at the Clinical Research Unit at DUMC under the supervision of Dr. Cynthia Kuhn. Plasma levels of norepinephrine and epinephrine were measured by highpressure liquid chromatography, followed by electrochemical detection. Data were collected with a computer-based data collection system and quantitated with the use of internal standard and external standard curves (32) . Cortisol was measured by specific radioimmunoassay using Coat-A-Count kit from Diagnostic Products Inc. Prolactin was measured by radioimmunoassay using a kit from DPC (Diagnostic Products) Coat-a-Count. The inter-and intra-assay coefficients of variation for catecholamines, cortisol, and prolactin were less than 10% and 5%, respectively.
Statistical Analysis
General linear models were used to examine the effects of tryptophan enhancement/depletion on neuroendocrine function. These models included repeated measures variables representing day (sham and active) and time of day (within each day). Because the tryptophan infusion and depletion procedures occurred for different periods (1 hour for infusion versus 4.5 hours for depletion), analyses were conducted separately for these conditions. Separate analyses were also conducted for each neuroendocrine variable. We also performed exploratory analyses to evaluate sex and race as moderators of the effects tryptophan enhancement and depletion on catecholamines. Values for the neuroendocrine variables were log transformed for use in analyses to achieve appropriate distributional properties. Analyses were conducted with SAS Version 9.1.
RESULTS
Tryptophan Depletion
There were significant day by time interactions for prolactin (F(5,335) = 4.22, p = .001) and cortisol (F(5,335) = 4.96, p = .0002). On both the active and the sham day, prolactin levels showed a similar magnitude of decrease across the 4.5-hour protocol, but the pattern of change on those 2 days was different (Table 1) . On the active day, prolactin levels decreased more during the first 3.5 hours of the protocol, whereas sham-day prolactin levels showed a larger decrease during the final hour of the protocol. Cortisol levels gradually decreased on both days during the protocol. However, on the day of active depletion, cortisol levels showed a greater decrease during the first 3.5 hours of the protocol and a greater increase during the final 1 hour of the protocol, resulting in higher levels of cortisol, relative to sham-day levels, by the end of the protocol. Tryptophan depletion also had an effect on catecholamine levels as indicated by significant day by time interactions for epinephrine (F(5,330) = 2.69, p = .021) and norepinephrine (F(5,335) = 2.79, p = .018). Levels of epinephrine rose during the morning hours on both the sham and the active day, but the magnitude of the change was greater during the active depletion day (Figure 1 ). Norepinephrine levels increased acutely on both the sham and active tryptophan depletion day (probably due to the averseness of the milkshake), after which norepinephrine levels gradually decreased during the following 3 hours during both the sham and active tryptophan depletion days. Norepinephrine levels continued to decrease during the last hour of the protocol on the sham day. In contrast, norepinephrine levels showed a marked increase during the final hour of the active tryptophan depletion protocol ( Figure 1 ).
Tryptophan Infusion
There were significant day by time interactions for plasma prolactin (F(3, 195) = 87.70, p < .0001) and cortisol (F(3,195) = 2.70, p = .047) ( Table 2 ). Prolactin and cortisol levels were stable across the sampling periods during the "sham" infusion day. In contrast, infusion of tryptophan resulted in a significant increase in both prolactin and cortisol during the active infusion day. There were also significant day by time interactions for plasma epinephrine (F(3,171) = 39.32, p < .0001) and plasma norepinephrine (F(3,195) = 31.09, p < .0001). As depicted in Figure 2 , shamday epinephrine and norepinephrine levels were stable across the sampling periods. Tryptophan infusion produced a dramatically different pattern of change in plasma epinephrine and norepinephrine. Plasma epinephrine increased by 58 pg/ml during the active infusion day compared with the small 2-pg/ml decrease seen on the sham infusion day. In marked contrast to the large epinephrine increase on the active day, plasma norepinephrine showed a marked decrease by 80 pg/ml at 12:00 PM on the active day. In comparison, norepinephrine showed a small increase on FIGURE 1. Mean norepinephrine and epinephrine levels (picogram per milliliter) from ingestion of amino acid milkshake at 7:30 AM during sham day (circles) and active tryptophan depletion (squares) day. 
Moderating Effects of Sex and Race
Exploratory analyses of the moderating effects of race and sex on catecholamine responses to the two protocols showed a significant day by time by sex interaction (p = .013) for epinephrine response to tryptophan depletion and a significant day by time by sex interaction for norepinephrine response to tryptophan infusion (p = .017). In the depletion arm, women showed similar epinephrine responses on sham and tryptophan depletion days, whereas in men, tryptophan depletion resulted in a greater epinephrine level increase on depletion day compared with sham day. In addition, women tended to show greater epinephrine responses during sham day compared with men, but men and women showed a similar epinephrine response on the active day. In the infusion arm, both men and women showed a reduction in norepinephrine on the active day versus the sham day, but this effect was more pronounced for men (see Figures S1 and S2 in Supplemental Digital Content 1, http://links.lww.com/PSYMED/A516). None of the interactions involving race were significant.
DISCUSSION
The major purpose of the present study was to explore the role of CNS 5-HT in the regulation of the SNS in humans. The results of this study suggest that as in previous research with animals, it has both excitatory and inhibitory effects. Infusion of tryptophan resulted in a marked increase in epinephrine and decrease in norepinephrine, whereas tryptophan depletion resulted in smaller increases in both epinephrine and norepinephrine. The effect of tryptophan infusion to increase epinephrine and decrease norepinephrine parallels earlier animal research that has shown that enhancing CNS levels of 5-HT can inhibit sympathetic outflow to the heart (8,9) but may also specifically stimulate the release of epinephrine from the adrenal medulla (13, 14) . Research with various animal species suggests that 5-HT 1A and 5-HT 2 receptors are involved in CNS regulation of SNS activity. There is evidence to suggest that 5-HT 1A receptors in the medullary raphe mediate an inhibitory effect of 5-HT on SNS activity (5-7). There is also evidence suggesting that both 5-HT 1A and 5-HT 2 receptors play a role in the sympathoexcitatory effects of 5-HT. For example, studies of rats have shown that both stimulation of 5-HT 1A receptors in the paraventricular nucleus of the hypothalamus and peripheral administration of a 5-HT 1A agonist can increase levels of circulating epinephrine (13, 14, 33) . Similarly, increases in circulating epinephrine have been observed after peripheral administration of a 5-HT 1C/2 receptor agonist to SpragueDawley rats (13, 14) . Studies using specific 5-HT 1A and 5-HT 2 receptor agonists and antagonists will be needed to further elucidate the receptor subtype(s) and their location that mediate the differential effects of 5-HT on norepinephrine and epinephrine.
Our findings in humans parallel earlier reports from animal studies that direct stimulation of CNS serotonergic receptors can have both excitatory and inhibitory effects on the SNS activity, suggesting that, like the effects on prolactin and cortisol, the locus of the opposite effects of tryptophan infusion on epinephrine and norepinephrine levels we observed is in the CNS. However, 5-HT is also synthesized in the periphery and 5-HT originating that there has been shown to modulate a range of cardiovascular functions, including effects on heart rate and vascular tone (34) (35) (36) . Therefore, it is possible that the change in epinephrine and/or norepinephrine levels reflect a peripheral effect of 5-HT. For example, peripherally administered 5-HT increases levels of epinephrine in canines, an effect believed to be mediated by 5-HT 2 receptors located on the adrenal medulla (37) . In addition, a dose-dependent increase of epinephrine has been observed in the rat after the administration of the peripheral acting 5-HT 1 /5-HT 2 receptor agonist α-methyl-5-HT (38) . Although our findings are consistent with previous research in animals showing that 5-HT acting in the CNS has inhibitory and excitatory effects on SNS activity, we cannot rule out the possibility that one or both of these effects could be due to the action of 5-HT on receptor sites in the periphery.
Active tryptophan depletion resulted in small and delayed increases in epinephrine and norepinephrine. Because this effect occurred just as study participants were preparing for the subsequent cardiovascular reactivity protocol, it may reflect the impact of lowering CNS 5-HT on participants' anticipatory physiological response to this stressor. This explanation is supported by a recent study that showed that lowering CNS 5-HT via tryptophan depletion resulted in enhanced stress-induced SNS activity (39) . The slight increase in catecholamine levels of the tryptophan depletion day may also FIGURE 2. Mean norepinephrine and epinephrine and levels (picogram per milliliter) from start of the infusion protocol at 11:00 AM during the sham day (circles) and the active tryptophan enhancement (squares) day. be due to negative mood resulting from tryptophan depletion (40) . It is interesting that both tryptophan depletion and enhancement resulted in an increase in epinephrine levels, although the effect of tryptophan depletion on epinephrine seemed to be of lesser magnitude. The similar effects of tryptophan depletion and enhancement on epinephrine levels may be due to a differential effect of those protocols on serotonergic activity in specific brain regions that govern inhibitory and excitatory effects on the SNS. For example, a tryptophan depletion mediated reduction in serotonergic activity at inhibitory 5-HT 1A receptors (5-7) might result in increased epinephrine levels, whereas a tryptophan enhancement mediated increase in serotonergic activity at excitatory 5-HT 1A and 5-HT 2 receptors in the paraventricular nucleus of the hypothalamus could result in increased epinephrine levels (13, 14, 33) . Different methodologies would need to be used to determine the exact locus of those effects. Finally, it is important to note that because active depletion always occurred on the final day of the study, we cannot rule out the presence of an order effect. It is possible that experiencing the aversive taste and adverse effects of the amino acid drink on the first day could alter participants' perception of the procedure and affect physiological responding on the active day.
Previous studies have reported sex differences in responses to tryptophan infusion and depletion in domains of functioning such as mood (41) (42) (43) and memory (44) . The present study extends those findings to acute catecholamine responses to tryptophan infusion and depletion. Sex differences are plausible given the known role of estrogen on serotonin synthesis transport, degradation, and pre-and postsynaptic serotonin receptors (45) (46) (47) (48) (49) . The precise source of the sex differences observed in the present study is not known but should be the focus of future research. Given the importance of catecholamines to human functioning (50, 51) , these findings may have implications for understanding sex differences in health and disease.
The larger increases in plasma prolactin and cortisol on the active infusion day are consistent with previously reported effects of CNS 5-HT enhancement on these hormones (4) . This confirms that the tryptophan enhancement protocol used in the present study successfully elevated CNS synaptic serotonin enough to have functional consequences. Although we observed larger initial decreases in prolactin levels on the active depletion day the magnitude of the decrease across the entire protocol was similar on active and sham days, a result that is consistent with previous studies (25, 52, 53) . It is noteworthy, however, that although tryptophan depletion does not seem to influence basal levels of prolactin, it does have functional consequences for pituitary function. For example, one study (25) reported that participants showed larger stress-induced changes in prolactin after tryptophan depletion in comparison with sham depletion. In addition, another study (52) reported that compared with the sham condition, active tryptophan depletion resulted in an attenuated prolactin response to fenfluramine challenge.
In conclusion, previous research in animals suggests that CNS 5-HT exerts both inhibitory and excitatory effects on SNS activity. The present study extends those findings to humans by showing that tryptophan infusion and depletion, known to produce varying CNS levels of 5-HT (18) (19) (20) (21) (22) (23) (24) 29) , have significant effects on SNS activity. Specifically, infusion of tryptophan resulted in an increase in epinephrine and a decrease in norepinephrine, whereas depletion of tryptophan resulted in an increase in both neurohormones. These findings suggest that in humans, CNS 5-HT activity influences patterns of SNS outflow in ways that could affect cardiovascular, metabolic, hemostatic, and immune system functions that are involved in a wide range of diseases. Further research will be required to determine whether the current study findings can be used to guide efforts to develop interventions targeting CNS serotonin activity as a means of reducing health-damaging effects of stress-induced increases in catecholamines.
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